GLP-1 Fear Overcome: Sleep Apnea Treatment Stocks Surge 6%

ResMed Inc. (NYSE: RMD) closed at $222.50 on the New York Stock Exchange, up 6.14%, lifting its market capitalization to $32.2 billion (approximately KRW 45 trillion). The single‐day share price gain alone added roughly $2.1 billion (about KRW 3 trillion) in enterprise value, while trading volume surged to 1.78 million shares—well above its recent average.

The stock’s sharp rise was driven by news that a major global bank added ResMed to its Asia-Pacific conviction list, coupled with growing anticipation ahead of the company’s fourth-quarter fiscal 2026 earnings report due August 6. On June 1, ResMed completed its $340 million (approximately KRW 470 billion) acquisition of Noctrix Health, broadening its wearable therapy portfolio for sleep and neurological disorders—such as restless legs syndrome—and reinforcing its growth narrative.

Headquartered in San Diego, ResMed is a global leader in sleep apnea and chronic respiratory care, supplying CPAP devices, masks and cloud-based software, and is viewed as a direct beneficiary of expansion in the home-based respiratory therapy market. While the rise of GLP-1 obesity treatments had stoked concerns about a potential decline in sleep apnea patients, analysts now point to significant structural growth drivers—including an aging population, improved diagnosis rates and the expansion of digital health platforms—as reasons for renewed optimism.